

Psychotropic Safety Monitoring Flowsheet

PATIENT NAME _____ INITIAL THERAPY PROVIDER _____ INITIAL PRESCRIBER _____

PATIENT DOB _____ DATE THERAPY BEGAN _____ INITIAL MEDICATION _____

PATIENT GENDER (Circle one.) MALE / FEMALE CLINIC/ LOCATION _____ DATE OF SIGNED CONSENT _____

PARENT/ GUARDIAN _____

BASIC (NON-INVASIVE) SAFETY MONITORING *(Record every visit!)*

	BASELINE/ PRE- TREATMENT	DATE	DATE	DATE	DATE	DATE	DATE	DATE	DATE	DATE	DATE	DATE	DATE
Reason: Therapy, medication management, or both													
Obesity Monitoring													
• Weight (kg)													
• Weight percentile score													
BMI													
BMI percentile score for age													
Height (cm)													
Height percentile score													
Blood pressure													
Urine pregnancy test													

BASELINE MONITORING *(For all new antipsychotic medications for children under age 18)*

DATE OBTAINED: _____

MINIMUM SET

- Fasting blood sugar _____
 Fasting LDL _____
 Fasting triglycerides _____
- Fasting total cholesterol _____
 Fasting HDL _____
- Other baseline labs*: _____

Psychotropic Safety Monitoring Flowsheet *(continued)*

PATIENT NAME _____	INITIAL THERAPY PROVIDER _____	INITIAL PRESCRIBER _____
PATIENT DOB _____	DATE THERAPY BEGAN _____	INITIAL MEDICATION _____
PATIENT GENDER <i>(Circle one.)</i> MALE / FEMALE	CLINIC/ LOCATION _____	DATE OF SIGNED CONSENT _____
PARENT/ GUARDIAN _____		

6-MONTH EVALUATION

DATE OBTAINED: _____

MINIMUM SET

- Fasting blood sugar _____ Fasting LDL _____ Fasting triglycerides _____
- Fasting total cholesterol _____ Fasting HDL _____
- Other baseline labs*: _____
-

12-MONTH EVALUATION

DATE OBTAINED: _____

MINIMUM SET

- Fasting blood sugar _____ Fasting LDL _____ Fasting triglycerides _____
- Fasting total cholesterol _____ Fasting HDL _____
- Other baseline labs*: _____
-

18-MONTH EVALUATION

DATE OBTAINED: _____

MINIMUM SET

- Fasting blood sugar _____ Fasting LDL _____ Fasting triglycerides _____
- Fasting total cholesterol _____ Fasting HDL _____
- Other baseline labs*: _____
-

**Baseline and repeated ECG should be considered for children prescribed many antipsychotics, including asenapine, iloperidone, droperidol, haloperidol, paliperidone, pimozide, quetiapine, risperidone, thioridazine and ziprasidone, and particularly when used with stimulants. Monitoring prolactin may be clinically indicated for those receiving antipsychotics with a high D2 receptor affinity. Vision exam/screening may be important to identify some complications. Fasting glucose assessment may be indicated for those showing abnormal fasting glucose and/or excess weight gain (more than 10% increase in percentile rank for weight or BMI). Lithium levels should be monitored if lithium is prescribed.*